BFM
KDNY

Boothbay Fund Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Boothbay Fund Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,852
Closed – – 2628
2022
Q4 		$0 Buy
+42,852
New +$949K ﹤0.01% 2598
2020
Q3 		– Sell
-94,045
Closed -$1.09M – 1297
2020
Q2 		$1.09M Sell
94,045
-5,526
-6% -$76.2K 0.07% 363
2020
Q1 		$1.36M Buy
99,571
+35,824
+56% +$424K 0.11% 227
2019
Q4 		$376K Buy
63,747
+48,788
+326% +$265K 0.03% 563
2019
Q3 		$79K Sell
14,959
-633
-4% -$4.2K 0.01% 712
2019
Q2 		$120K Buy
15,592
+326
+2% +$4.96K 0.01% 654
2019
Q1 		$304K Buy
15,266
+5,025
+49% +$87.6K 0.03% 503
2018
Q4 		$135K Buy
+10,241
New +$205K 0.02% 526

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boothbay Fund Management's KDNY Position: Q1 2023 in Review

Boothbay Fund Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 42,852 shares.

Boothbay Fund Management first reported a position in KDNY in Q4 2018 and held it in 8 quarters. The position peaked at $1.36M in Q1 2020. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

  • Boothbay Fund Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 42,852 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023.
  • Boothbay Fund Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2018 and held it in 8 quarters.
  • Boothbay Fund Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.36M in Q1 2020.
  • 157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.